(VIANEWS) – The NASDAQ ended the session with Catalyst Pharmaceuticals rising 13.33% to $7.31 on Thursday, following the last session’s upward trend. NASDAQ Composite rose 0.59% to $15,715.26, after two consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.
Volume
Today’s last reported volume for Catalyst Pharmaceuticals is 1763560, 109.51% above its average volume of 841743.
Catalyst Pharmaceuticals’s last close was $6.45, 11.89% below its 52-week high of $7.32.
Catalyst Pharmaceuticals’s Sales
Catalyst Pharmaceuticals’s sales growth is 18% for the current quarter and 15.6% for the next.
Catalyst Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 126.9M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Catalyst Pharmaceuticals’s stock is considered to be overbought (>=80).
Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $7.31 at 16:14 EST, under its 52-week high of $7.32 and way higher than its 52-week low of $3.22.
Catalyst Pharmaceuticals’s Moving Average
Catalyst Pharmaceuticals’s worth is way higher than its 50-day moving average of $5.85 and way above its 200-day moving average of $5.56.
More news about Catalyst Pharmaceuticals (CPRX).
